Page 184 - CW E-Magazine (9-1-2024)

Special Report Special Report

betes in June 2022, and was approved capacity for products in its chronic dis- represents the largest manufacturing for potential new tumour types or ex- customary closing conditions. Immuno- tive substances (NASs) have launched
in the US for chronic weight manage- ease portfolio, including GLP-1 pro- investment at a single location in the panded indications in earlier lines of Gen’s key commercial product is Elahere globally in the past fi ve years and 237
ment in early November 2023. For ducts. In November 2023, the company company’s history. therapy, with catalysts expected annu- (mirvetuximab soravtansine-gynx), an over the last 20 years.
Novo Nordisk, sales for the fi rst nine announced an investment of more than ally through 2027. ADC for treating platinum-resistant ovar-
months of 2023 within its Diabetes DKK 42-bn ($6.1-bn) starting in 2023 In March 2023, Lilly broke ground ian cancer. The acquisition accelerates Global economy slows, but infl ation
and Obesity care segment increased by to expand existing manufacturing faci- on a new $1-bn biotech manufacturing The proposed acquisition is ex- AbbVie’s commercial and clinical pre- abates
36% in Danish kroner (DKK) to DKK lities in Kalundborg, Denmark, for campus in Raheen, County Limerick, pected to enable combination poten- sence in the solid tumour space. Addition- Infl ationary pressures represented
153.8-bn ($22.5-bn), mainly driven by additional capacity across the value chain Ireland, which will be Lilly’s most tial across both Seagen’s and Pfi zer’s ally, ImmunoGen’s follow-on pipeline the number one issue in 2022, but
GLP-1 diabetes sales growth of 45% in from manufacturing of active pharma- advanced manufacturing site for existing pipelines and to use Pfi zer’s protein of ADCs further complements AbbVie’s infl ation abated in 2023 although the
Danish kroner and Obesity care grow- ceutical ingredients (APIs) to packag- monoclonal antibodies. This site will engineering and medicinal chemistry ADC platform and existing programmes. global economy as a whole is expected
ing by 167% in Danish Kroner to DKK ing, with the vast majority invested in produce existing products as well as the capabilities to advance Seagen’s ADC to see slowing growth. Global growth
30.4-bn ($4.4-bn). API capacity. The new API facility will company’s pipeline of clinical products technology for potential new target Oncology continues to be high- is set to remain modest, with the im-
be designed as a multi-product facility, by 2026. Additionally, the company combinations and new biologics. Sea- growth therapeutic sector pact of the necessary monetary policy
Novo Nordisk’s multibillion-dollar with fl exibility to accommodate current plans to invest $500-mn in Limerick gen is also advancing technologies Pfi zer’s and AbbVie’s deal for tightening, weak trade, and lower
manufacturing expansions and future processes. The facility will to create a new biologics active ingre- capable of potentially generating multiple oncology-focused ADC companies re- business and consumer confi dence be-
Hand-in-hand with the product suc- have a footprint of 170,000-m . The dients site. The new $1.5-bn combined investigational new drug applications, fl ects a larger and continued trend in ing increasingly felt, according to the
2
cess of Novo Nordisk’s diabetes and construction projects will be fi nalized investment in Ireland is in addition to including new linker/payload techno- the bio/pharmaceutical industry: the Organization for Economic Coopera-
weight-management drugs is increased gradually from the end of 2025 through an $1-bn investment that the company logies for ADCs and other antibody strength of the oncology drug market. tion and Development’s (OECD) latest
demand for manufacturing capacity, 2029. announced in January 2022, for a new platforms that directly engage the Oncology drugs, the largest therapeutic Economic Outlook, issued in Novem-
and the company is advancing one of injectable products and devices manu- immune system to destroy tumours, sector globally and in the US, continues ber 2023.
the largest manufacturing expansions Lilly’s multi-billion dollar manufac- facturing site in Concord, North Caro- such as bispecifi c antibodies. to be a major driver of growth. Overall,
announced in 2023. turing expansions lina. on a global basis, spending on cancer The OECD projects global growth
Lilly also is progressing multi- At the time of the merger announce- medicines rose to $196-bn globally in GDP of 2.9% in 2023, followed by
It is investing DKK 16-bn ($2.3-bn) billion manufacturing expansions in Pfi zer’s pending $43-bn acquisition ment in March 2023, Seagen said it ex- in 2022, growing at an average 12% a mild slowdown to 2.7% in 2024 and
over the next four years to expand its large measure due to growth in its dia- of Seagen pects to generate approximately $2.2-bn annually over the last fi ve years, accord- a slight improvement to 3.0% in 2025.
production site in Chartres, France, for betes product portfolio. In November Pfi zer’s pending $43-bn acquisi- of revenue in 2023, representing ing to a recent study, ‘Global Oncology Asia is expected to continue to account
its current and future product portfolio 2023, the company announced plans tion of Seagen, a Bothell, Washington- 12% year-over-year growth, from its Trends 2023: Outlook to 2027’, by for the bulk of global growth in 2024-
within serious chronic diseases. The to construct a new $2.5-bn injectable based bio/pharmaceutical company four in-line medicines, royalties, and the IQVIA Institute for Human Data 25, as it has in 2023. Consumer price
investment will increase the capacity of manufacturing site in Alzey, Rhine- specializing in antibody-drug conju- collaboration and license agreements. Science. The growth in major markets infl ation is expected to continue to ease
the manufacturing site by adding asep- land-Palatinate, Germany. This new gates (ADCs) and drugs for oncology, When combining the expected growth is driven by new products and brand gradually back toward central bank tar-
tic production and fi nished production facility will further expand the com- was one of the largest deals in 2023 in trajectories for these medicines with volume, and offset by losses of exclu- gets in most economies by 2025, as cost
capacity and expanding the company’s pany’s global parenteral (injectable) the bio/pharmaceutical industry. The candidates that could emerge from Sea- sivity, including biosimilar impact. pressures moderate. Consumer price in-
current quality-control laboratory. The product and device manufacturing net- deal, announced in March 2023, is ex- gen’s pipeline, subject to clinical trial fl ation in OECD countries is expected
investment includes capacity for gluca- work and support increased demand for pected to be completed in early 2024, and regulatory success, Pfi zer said at Spending on oncology medicines to decline from 7.0% in 2023 to 5.2%
gon-like peptide-1 (GLP-1) products. Lilly’s medicines, including its diabe- subject to the fulfi lment of customary the time of the merger announcement is expected to reach $375-bn by 2027, in 2024 and 3.8% in 2025.
The Chartres site now employs around tes and obesity portfolio. Construction closing conditions, including receipt of that it believes Seagen could contribute according to the IQVIA Institute analysis.
1,600 people, and the production facility is scheduled to begin in 2024, and the required regulatory approvals. more than $10-bn in risk-adjusted reve- The US spending on oncology medi- Growth in the US is projected at
manufactures products to treat diabetes. new site is scheduled to be operational nues in 2030, with potential signifi cant cines has risen from $58-bn in 2018 2.4% in 2023, before slowing to 1.5%
Novo’s GLP-1 products include the beginning in 2027. Seagen’s portfolio includes four growth beyond 2030. to $88-bn in 2022, representing 45% in 2024, and then picking up slightly
diabetes drug, Ozempic (semaglutide). approved medicines that are indicated of global spending. Growth in the US to 1.7% in 2025 as monetary policy is
In addition, in April 2023, Lilly across solid tumours and hematologic AbbVie’s pending $10.1-bn acquisi- is expected to increase to the 12-15% expected to ease. In the Euro area,
The new facilities will more than announced that it will invest an additional malignancies, including three ADCs: tion of Immunogen range as more than 100 new drugs which had been relatively hard hit by
double the footprint of the site. The faci- $1.6-bn at its two new manufacturing Adcetris (brentuximab vedotin), Padcev Another deal in the ADC space, is are anticipated to launch across novel the war in Ukraine and the energy price
lity will be designed as a multi-product sites within the LEAP Innovation Park (enfortumab vedotin), and Tivdak AbbVie’s pending $10.1-bn acquisi- modalities and frequently moving to shock, GDP growth is projected at 0.6%
facility to accommodate current and in Boone County, Indiana. In May 2022, (tisotumab vedotin). The company also tion of Immunogen, a Waltham, Mas- earlier lines of therapy; increases in in 2023, before rising to 0.9% in 2024
future processes. The construction pro- it announced a $2.1-bn investment to commercializes Tukysa (tucatinib), sachusetts-based bio/pharmaceutical spending will, however, be offset by and 1.5% in 2025. China is expected to
ject has now been initiated and will build the two new facilities to expand which was approved in January 2023 company developing ADCs. The deal, patent expiries for small molecules grow at a 5.2% in 2023, before growth
gradually be fi nalized from 2026 to 2028. Lilly’s manufacturing network for for treating certain types of colorectal announced in November 2023, is and biologics, according to the IQVIA drops to 4.7% in 2024 and 4.2% in
active ingredients and new therapeutic cancer in combination with trastuzumab. expected to close in the middle of 2024, Institute’s analysis. 2025 on the back of ongoing stresses
This is a second major investment modalities, such as genetic medicines. Clinical development programmes are subject to ImmunoGen shareholder in the real estate sector and continued
by the company to increase production The now combined $3.7-bn investment ongoing for each of these medicines approval, regulatory approvals, and other A total of 115 oncology novel ac- high household saving rates.

184 Chemical Weekly January 9, 2024 Chemical Weekly January 9, 2024 185

Contents Index to Advertisers Index to Products Advertised